Qiagen ($QGEN) snatched up AmniSure International this week as the company continued to beef up its diagnostic offerings through acquisitions. AmniSure, a privately held company based in Boston, is known for marketing a point-of-care diagnostic that determines if a pregnant woman is suffering from a rupture of fetal membranes.
Thanks but no thanks. That was GlaxoSmithKline CEO Andrew Witty's comeback to the suggestion that maybe GSK should buy AstraZeneca.
A buyout, he said, would be "very distracting".
Biotech shareholders don't want to sell at bargain prices. Pharma doesn't want to pay big premiums. Who's going to prevail?
Bloomberg dug into the numbers to find Warner Chilcott delivers some sweet free cash flow, about 10 times more than the median among other specialty drugmakers.
The cash deal delivers AP214, in development to prevent acute kidney injury associated with major cardiac surgery.
Synexus, a European recruitment and trial management firm, announced its acquisition of Polish CRO Osteomed.
Novartis has snapped up Fougera Pharmaceuticals, a U.S.-based maker of generic skin treatments, for $1.5 billion.
Every week, it seems, a new biotech deal hits the radar screens. What's stopping the buyouts? Reuters' Ben Hirschler concludes that a handful of big shareholders at each of the target companies simply aren't interested in catering to Big Pharma's appetite for a bargain.
Johnson & Johnson ($JNJ) made a big move in China this week with the purchase of its first medical device company in that country. It picked up Guangzhou Bioseal Biotech for an undisclosed sum.